Similarly, Zhang et al. [87] have modified RBCM-NPs by employing a lipid insertion approach to add recombinant anti-EGFR-iRGD to the particle surface, allowing them to achieve successful and accurate tumor-targeting in a high EGFR-expressing colorectal cancer model, whereas NPs without peptide modification were less efficacious. This evidence concerns the gene EGFR and neoplasm.